Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Praxis Precision Medicines filings document regulatory disclosures for a CNS-focused biopharmaceutical issuer with common stock listed on the Nasdaq Global Select Market under PRAX. Its Form 8-K and 8-K/A reports cover material events, operating and financial results, clinical and regulatory updates, capital-structure disclosures, and leadership or board changes.
The company’s filing record includes disclosures related to ulixacaltamide HCl for essential tremor, elsunersen in SCN2A developmental and epileptic encephalopathy, and broader pipeline programs in movement disorders and epilepsy. Proxy materials address annual meeting matters, board composition, committee assignments, executive compensation, equity awards and other governance subjects.
Praxis Precision Medicines (PRAX) reported insider activity by its Principal Accounting Officer on a Form 4. On 11/20/2025, the officer exercised multiple stock options, acquiring Praxis common stock at exercise prices of $49.5, $83.85, $133.65, $43.37, $44.4, and $56.94 per share. The same day, the officer sold 11,455 shares at a weighted average price of $191.958 and 2,145 shares at a weighted average price of $192.711, in multiple transactions within narrow price ranges. After these transactions, the officer beneficially owned 10,441.656 shares of Praxis common stock directly. The filing notes that the transactions were effected for estate planning purposes, and several option grants referenced were already fully vested or continue to vest over time.
Praxis Precision Medicines (PRAX) filed its Q3 2025 report, showing higher R&D investment as late‑stage programs advance and a larger quarterly loss. Cash, cash equivalents and marketable securities were $389.2 million as of September 30, 2025. The company also completed an October 2025 public offering with $567.0 million in net proceeds, and states these resources will fund operations for at least one year from issuance and support program activities into 2028.
Q3 operating expenses reached $78.4 million (R&D $65.8 million; G&A $12.6 million), driving a net loss of $73.9 million versus $51.9 million a year ago. For the nine months, operating cash use was $172.7 million, offset by financing inflows including $89.3 million from at‑the‑market offerings. PRAX reported $14.8 million of other income year‑to‑date.
Shares outstanding were 21,165,933 as of September 30, 2025, and 25,007,171 as of October 31, 2025. Management highlights progress across ulixacaltamide (positive Phase 3 topline in October 2025), vormatrigine, relutrigine and elsunersen, while noting continued losses as development advances.
Praxis Precision Medicines (PRAX) filed its Q3 2025 report, showing higher R&D investment as late‑stage programs advance and a larger quarterly loss. Cash, cash equivalents and marketable securities were $389.2 million as of September 30, 2025. The company also completed an October 2025 public offering with $567.0 million in net proceeds, and states these resources will fund operations for at least one year from issuance and support program activities into 2028.
Q3 operating expenses reached $78.4 million (R&D $65.8 million; G&A $12.6 million), driving a net loss of $73.9 million versus $51.9 million a year ago. For the nine months, operating cash use was $172.7 million, offset by financing inflows including $89.3 million from at‑the‑market offerings. PRAX reported $14.8 million of other income year‑to‑date.
Shares outstanding were 21,165,933 as of September 30, 2025, and 25,007,171 as of October 31, 2025. Management highlights progress across ulixacaltamide (positive Phase 3 topline in October 2025), vormatrigine, relutrigine and elsunersen, while noting continued losses as development advances.
Praxis Precision Medicines (PRAX) reported that it announced its financial results for the quarter ended September 30, 2025. The company furnished a press release detailing these results as Exhibit 99.1.
The information under Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liability, nor incorporated by reference unless specifically stated. PRAX’s common stock trades on The Nasdaq Global Select Market under the symbol PRAX.
Praxis Precision Medicines (PRAX) reported that it announced its financial results for the quarter ended September 30, 2025. The company furnished a press release detailing these results as Exhibit 99.1.
The information under Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liability, nor incorporated by reference unless specifically stated. PRAX’s common stock trades on The Nasdaq Global Select Market under the symbol PRAX.
Praxis Precision Medicines (PRAX) furnished an updated corporate presentation for investor meetings and disclosed a regulatory update for ulixacaltamide. The presentation is available on its website and is furnished as Exhibit 99.1 under Item 7.01.
Separately, the company reported that the FDA, after reviewing Essential3 topline results, granted a Type B meeting for ulixacaltamide to take place in the fourth quarter of 2025. Information provided under Item 7.01 is furnished and not deemed filed under the Exchange Act.
Praxis Precision Medicines announced an underwritten equity offering of 3,025,480 shares of common stock and pre-funded warrants to purchase up to 318,470 shares. The shares were priced at $157.00 each and the pre-funded warrants at $156.9999 per underlying share, reflecting a $0.0001 exercise price. The underwriters’ 30-day option to purchase up to 501,592 additional shares was exercised in full on October 17, 2025.
All securities are being sold by the company, with expected net proceeds of approximately $567.0 million after underwriting discounts and expenses, giving effect to the option exercise. Closing is expected on October 20, 2025, subject to customary conditions. The pre-funded warrants are immediately exercisable, permit cashless exercise, include 4.99% or 9.99% beneficial ownership limits (adjustable up to 19.99% on 61 days’ notice), and will not be listed on Nasdaq. The company plans to use proceeds to advance clinical programs, prepare for potential commercialization of late-stage assets, and for working capital, stating funding into 2028 when combined with existing cash.
Praxis Precision Medicines (PRAX) launched a primary offering of 3,025,480 shares of common stock at $157.00 per share and pre-funded warrants to purchase up to 318,470 shares at $156.9999 per underlying share. The company expects gross proceeds of $525,000,118.15, underwriting discounts of $31,500,009.00, and proceeds before expenses of $493,500,109.15. Underwriters have a 30-day option to buy up to 501,592 additional shares.
The company estimates net proceeds of approximately $493.0 million and plans to use them, together with existing cash, to fund R&D, prepare for potential commercialization of late-stage assets, advance earlier-stage programs, and for working capital and general purposes. Shares outstanding were 21,165,933 as of September 30, 2025, and are expected to be 24,191,413 immediately after the offering, excluding shares issuable upon exercise of the pre-funded warrants. The pre-funded warrants are exercisable at any time, carry a $0.0001 exercise price, and are subject to a 4.99% (or 9.99%) beneficial ownership limitation.
Praxis Precision Medicines (PRAX): insider transaction reported. Affiliated entities of Adage Capital reported multiple open‑market sales of Common Stock on 10/16/2025 across several tranches at weighted‑average prices ranging from $90.0025 to $140.0000. One disclosed tranche was 250,000 shares at $104.3095.
Following these sales, the reporting persons beneficially owned 2,060,175 PRAX shares indirectly. The securities are held by Adage Capital Partners, L.P., with Adage Capital Management, L.P. as investment manager; Robert Atchinson and Phillip Gross are managing members of related general partners. The reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest.
Praxis Precision Medicines (PRAX) reported positive topline Phase 3 results for ulixacaltamide in essential tremor. In Study 1, the placebo-controlled parallel study, ulixacaltamide produced a statistically significant and clinically meaningful improvement in the mADL11 primary endpoint at Week 8 (p<0.0001), with effects evident from Week 2 and sustained through 12 weeks. All key secondary endpoints in Study 1 reached statistical significance.
In Study 2, a randomized withdrawal design, 55% of patients continuing ulixacaltamide maintained response versus 33% on placebo (p=0.0369; OR=2.7). The first key secondary endpoint (rate of disease improvement) was significant; PGI-C and CGI-S favored ulixacaltamide numerically. Ulixacaltamide was generally well tolerated, with no deaths and no drug-related serious adverse events; common adverse events included dizziness and brain fog. The company has requested a pre-NDA meeting with the FDA and plans to submit an NDA by early 2026, upon agreement with the agency.
Praxis Precision Medicines (PRAX) reported positive topline Phase 3 results for ulixacaltamide in essential tremor. In Study 1, the placebo-controlled parallel study, ulixacaltamide produced a statistically significant and clinically meaningful improvement in the mADL11 primary endpoint at Week 8 (p<0.0001), with effects evident from Week 2 and sustained through 12 weeks. All key secondary endpoints in Study 1 reached statistical significance.
In Study 2, a randomized withdrawal design, 55% of patients continuing ulixacaltamide maintained response versus 33% on placebo (p=0.0369; OR=2.7). The first key secondary endpoint (rate of disease improvement) was significant; PGI-C and CGI-S favored ulixacaltamide numerically. Ulixacaltamide was generally well tolerated, with no deaths and no drug-related serious adverse events; common adverse events included dizziness and brain fog. The company has requested a pre-NDA meeting with the FDA and plans to submit an NDA by early 2026, upon agreement with the agency.
Praxis Precision Medicines (PRAX) reported positive topline Phase 3 results for ulixacaltamide in essential tremor. In Study 1, the placebo-controlled parallel study, ulixacaltamide produced a statistically significant and clinically meaningful improvement in the mADL11 primary endpoint at Week 8 (p<0.0001), with effects evident from Week 2 and sustained through 12 weeks. All key secondary endpoints in Study 1 reached statistical significance.
In Study 2, a randomized withdrawal design, 55% of patients continuing ulixacaltamide maintained response versus 33% on placebo (p=0.0369; OR=2.7). The first key secondary endpoint (rate of disease improvement) was significant; PGI-C and CGI-S favored ulixacaltamide numerically. Ulixacaltamide was generally well tolerated, with no deaths and no drug-related serious adverse events; common adverse events included dizziness and brain fog. The company has requested a pre-NDA meeting with the FDA and plans to submit an NDA by early 2026, upon agreement with the agency.
Praxis Precision Medicines launched a primary offering of common stock and is also offering pre-funded warrants, with an underwriters’ 30‑day option to buy additional shares. The pre-funded warrants carry a $0.0001 per‑share exercise price and are subject to ownership limits. Proceeds are earmarked for R&D, late‑stage commercialization preparation, earlier‑stage programs, working capital and general corporate purposes.
The company reported positive topline Phase 3 Essential3 results for ulixacaltamide in essential tremor. In Study 1, the primary endpoint showed a 4.3‑point mean improvement in mADL11 at Week 8 (p<0.0001), sustained through 12 weeks, with all key secondary endpoints statistically significant. In Study 2, 55% maintained response on ulixacaltamide vs 33% on placebo (p=0.0369; OR=2.7).
Safety was generally consistent with prior experience: most common adverse events included constipation, dizziness, euphoric mood, brain fog, headache, paraesthesia and insomnia; there were no deaths and no drug‑related serious adverse events. Praxis has submitted a pre‑NDA meeting request to the FDA and plans to submit the NDA by early 2026.
Praxis Precision Medicines launched a primary offering of common stock and is also offering pre-funded warrants, with an underwriters’ 30‑day option to buy additional shares. The pre-funded warrants carry a $0.0001 per‑share exercise price and are subject to ownership limits. Proceeds are earmarked for R&D, late‑stage commercialization preparation, earlier‑stage programs, working capital and general corporate purposes.
The company reported positive topline Phase 3 Essential3 results for ulixacaltamide in essential tremor. In Study 1, the primary endpoint showed a 4.3‑point mean improvement in mADL11 at Week 8 (p<0.0001), sustained through 12 weeks, with all key secondary endpoints statistically significant. In Study 2, 55% maintained response on ulixacaltamide vs 33% on placebo (p=0.0369; OR=2.7).
Safety was generally consistent with prior experience: most common adverse events included constipation, dizziness, euphoric mood, brain fog, headache, paraesthesia and insomnia; there were no deaths and no drug‑related serious adverse events. Praxis has submitted a pre‑NDA meeting request to the FDA and plans to submit the NDA by early 2026.
Praxis Precision Medicines launched a primary offering of common stock and is also offering pre-funded warrants, with an underwriters’ 30‑day option to buy additional shares. The pre-funded warrants carry a $0.0001 per‑share exercise price and are subject to ownership limits. Proceeds are earmarked for R&D, late‑stage commercialization preparation, earlier‑stage programs, working capital and general corporate purposes.
The company reported positive topline Phase 3 Essential3 results for ulixacaltamide in essential tremor. In Study 1, the primary endpoint showed a 4.3‑point mean improvement in mADL11 at Week 8 (p<0.0001), sustained through 12 weeks, with all key secondary endpoints statistically significant. In Study 2, 55% maintained response on ulixacaltamide vs 33% on placebo (p=0.0369; OR=2.7).
Safety was generally consistent with prior experience: most common adverse events included constipation, dizziness, euphoric mood, brain fog, headache, paraesthesia and insomnia; there were no deaths and no drug‑related serious adverse events. Praxis has submitted a pre‑NDA meeting request to the FDA and plans to submit the NDA by early 2026.
Mitchell Dean J, a director of Praxis Precision Medicines, Inc. (PRAX), reported multiple option exercises and resulting share holdings on 09/24/2025. He acquired 1,932 shares via exercise at $14.36, 8,566 shares at $44.25 and 1,753 shares at $44.04, increasing his direct beneficial ownership to 17,251 shares. The related options have varying vesting histories: the $14.36 option fully vested 06/12/2024, the $44.25 option fully vested 06/05/2025, and the $44.04 option vests monthly over one year starting 06/26/2025. The reported transactions were filed by an attorney-in-fact on 09/25/2025.